Stefanie Höfer
@stefaniehoefer.bsky.social
Reposted by Stefanie Höfer
New paper!
Our chemoproteomic survey of phenylhydroxamic acids identifies the first drug-like inhibitors for nucleotide-binding protein HINT1 and nucleoside kinases NME1-4. On top, we found probes for the HDAC inhibitor off-target MBLAC2. Check out the open-access article! tinyurl.com/yh92vh6b
Our chemoproteomic survey of phenylhydroxamic acids identifies the first drug-like inhibitors for nucleotide-binding protein HINT1 and nucleoside kinases NME1-4. On top, we found probes for the HDAC inhibitor off-target MBLAC2. Check out the open-access article! tinyurl.com/yh92vh6b
sev on X: "Paper alert! We report the first inhibitors for nucleoside kinases NME1-4 and for the nucleotide-binding protein HINT1. On top, we provide probes for MBLAC2, an off-target of every second (!) hydroxamic acid-based HDAC inhibitor! https://t.co/uuRCO78xFz 👇🧵" / X
Paper alert! We report the first inhibitors for nucleoside kinases NME1-4 and for the nucleotide-binding protein HINT1. On top, we provide probes for MBLAC2, an off-target of every second (!) hydroxamic acid-based HDAC inhibitor! https://t.co/uuRCO78xFz 👇🧵
x.com
May 9, 2025 at 11:33 AM
New paper!
Our chemoproteomic survey of phenylhydroxamic acids identifies the first drug-like inhibitors for nucleotide-binding protein HINT1 and nucleoside kinases NME1-4. On top, we found probes for the HDAC inhibitor off-target MBLAC2. Check out the open-access article! tinyurl.com/yh92vh6b
Our chemoproteomic survey of phenylhydroxamic acids identifies the first drug-like inhibitors for nucleotide-binding protein HINT1 and nucleoside kinases NME1-4. On top, we found probes for the HDAC inhibitor off-target MBLAC2. Check out the open-access article! tinyurl.com/yh92vh6b
Reposted by Stefanie Höfer
🚀 Exciting news from our lab! Our latest paper has been featured on the cover of @molsystbiol.org - "Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response" by Höfer et al.! 🧬🎉 doi.org/10.1038/s44320-025-00085-6 (1/4)
Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response | Molecular Systems Biology
imageimagePhosphoproteomics unveils the mode of action of clinical ATR inhibitors and explains
their synergy with Gemcitabine in pancreatic cancer cells. Viability screening of 146 targeted drugs ide...
doi.org
March 4, 2025 at 4:06 PM
🚀 Exciting news from our lab! Our latest paper has been featured on the cover of @molsystbiol.org - "Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response" by Höfer et al.! 🧬🎉 doi.org/10.1038/s44320-025-00085-6 (1/4)
Reposted by Stefanie Höfer
@kusterlab.bsky.social lab suggests chemoresistance to DNA damaging agent Gemcitabine may be overcome with synergistic action of ATR kinase inhibitors ➡️ www.embopress.org/doi/full/10....
February 4, 2025 at 2:47 PM
@kusterlab.bsky.social lab suggests chemoresistance to DNA damaging agent Gemcitabine may be overcome with synergistic action of ATR kinase inhibitors ➡️ www.embopress.org/doi/full/10....